Latest Platform Technology News

Vinyl Group Ltd has reported a striking 190% revenue increase in FY25, driven by strategic acquisitions and organic growth, and is targeting its first profitable quarter by December 2025 with AI-powered publishing expansion.

Immuron Limited has secured FDA approval for its IMM-529 Investigational New Drug application, clearing the way for a Phase 2 clinical trial targeting Clostridioides difficile infection. This milestone marks a significant step forward for a novel oral antibody therapy addressing a critical infectious disease with high recurrence rates.

Noxopharm Limited reports growing interest in its Sofra technology with new research collaborations and a safe, well-tolerated HERACLES trial of SOF-SKN. The company also secures funding extensions to support ongoing development.

Streamplay Studio Limited reports its second consecutive cash-flow positive quarter, driven by strong game launches and platform growth across Tier 1 markets and emerging regions.

Starpharma has secured a $5.5 million upfront payment from Genentech as part of a new collaboration to develop dendrimer-drug conjugates targeting cancer therapies. The partnership includes potential milestone payments exceeding half a billion dollars and tiered royalties.

Invion Limited has partnered with Protect Animal Health to explore Photosoft™, a novel photodynamic therapy, as a treatment for cancer in companion animals, targeting a booming pet cancer market.

Australian Finance Group Ltd (AFG) reported a robust 21% increase in net profit for FY25, driven by strategic broker network expansion and technology investments, while setting ambitious growth goals through FY29.

PlaySide Studios has extended its development contract with Meta Platforms for Horizon Worlds by 12 months, reinforcing its revenue outlook through 2026.

Tetratherix Limited advances its Tetramatrix biomaterial platform with a robust IP portfolio, scalable manufacturing, and strategic partnerships aimed at commercialising across multiple clinical franchises.

Tetratherix Limited reports its first financial results as a listed company, revealing a $9.4 million statutory loss driven by R&D and listing costs, alongside a robust $29.3 million cash position post-IPO. The company highlights key operational milestones and outlines strategic plans to accelerate commercialisation across its innovative biomaterial platform.

Tetratherix Limited reported a $9.4 million statutory loss for FY25 amid significant R&D and operational investments, successfully listing on the ASX and progressing multiple clinical and manufacturing initiatives.

Calix Limited reported a $20.1 million loss for FY2025 despite an 11.2% increase in revenue, reflecting ongoing investment in its industrial decarbonisation technology platform.